- Home
- SLDP vs CTMX Comparison
SLDP vs CTMX Comparison
Compare SLDP & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDP
- CTMX
- Stock Information
- Founded
- SLDP 2011
- CTMX 2008
- Country
- SLDP United States
- CTMX United States
- Employees
- SLDP N/A
- CTMX N/A
- Industry
- SLDP Electrical Products
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- SLDP Energy
- CTMX Health Care
- Exchange
- SLDP Nasdaq
- CTMX Nasdaq
- Market Cap
- SLDP 394.6M
- CTMX 444.3M
- IPO Year
- SLDP N/A
- CTMX 2015
- Fundamental
- Price
- SLDP $3.10
- CTMX $2.39
- Analyst Decision
- SLDP Buy
- CTMX Strong Buy
- Analyst Count
- SLDP 2
- CTMX 2
- Target Price
- SLDP $1.50
- CTMX $5.00
- AVG Volume (30 Days)
- SLDP 8.6M
- CTMX 2.4M
- Earning Date
- SLDP 08-05-2025
- CTMX 08-07-2025
- Dividend Yield
- SLDP N/A
- CTMX N/A
- EPS Growth
- SLDP N/A
- CTMX 128.27
- EPS
- SLDP N/A
- CTMX 0.49
- Revenue
- SLDP $20,202,000.00
- CTMX $147,557,000.00
- Revenue This Year
- SLDP $28.39
- CTMX N/A
- Revenue Next Year
- SLDP $38.07
- CTMX N/A
- P/E Ratio
- SLDP N/A
- CTMX $4.91
- Revenue Growth
- SLDP 3.22
- CTMX 23.81
- 52 Week Low
- SLDP $0.68
- CTMX $0.40
- 52 Week High
- SLDP $3.21
- CTMX $3.10
- Technical
- Relative Strength Index (RSI)
- SLDP 75.43
- CTMX 52.18
- Support Level
- SLDP $2.38
- CTMX $2.36
- Resistance Level
- SLDP $2.70
- CTMX $2.79
- Average True Range (ATR)
- SLDP 0.26
- CTMX 0.17
- MACD
- SLDP 0.05
- CTMX -0.02
- Stochastic Oscillator
- SLDP 89.12
- CTMX 44.25
About SLDP Solid Power Inc.
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization strategy is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.